Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Aclarion, Inc. ( (ACON) ) is now available.
On January 8, 2026, Aclarion, Inc. entered into a Securities Purchase Agreement for a registered direct offering of 200,000 shares of common stock at $5.18 per share and pre-funded warrants to purchase up to 1.8 million additional shares, with the transaction expected to close on or about January 9, 2026, subject to customary conditions. The deal, which is expected to generate approximately $10.36 million in gross proceeds before fees, is structured so that the pre-funded warrants are immediately exercisable at a nominal exercise price but subject to ownership limits, and the company plans to use the net proceeds to support market development, The Clarity Trial, product development and quality initiatives, and general corporate purposes, underscoring an effort to bolster its balance sheet and fund ongoing growth and clinical programs while engaging Dawson James Securities as exclusive placement agent.
The most recent analyst rating on (ACON) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Aclarion, Inc. stock, see the ACON Stock Forecast page.
More about Aclarion, Inc.
Aclarion, Inc. is a publicly traded company that raises capital through registered offerings of its common stock and related securities to fund market development initiatives, clinical evidence generation, a study known as The Clarity Trial, product development and quality efforts, and general corporate and administrative support, indicating a focus on advancing and commercializing its medical or technology solutions in regulated markets.
Average Trading Volume: 875,222
Technical Sentiment Signal: Sell
Current Market Cap: $3.86M
For an in-depth examination of ACON stock, go to TipRanks’ Overview page.